Profile data is unavailable for this security.
About the company
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets. This segment includes subsidiary companies, which include Vedanta Biosciences, Inc., Gelesis, Inc., Akili Interactive Lab, Inc., Tal Medical, Inc., Karuna Pharmaceuticals, Inc., Entrega Inc. and Follica Incorporated. Businesses in the project phase businesses segment are those whose activities are focused on financing, sourcing and creating new product candidates and newly created businesses whose technologies are in the process of validation. This segment includes subsidiary companies, which include The Sync Project Inc., Sonde Health, Inc., Commense Inc., Alivio Therapeutics, Inc., Vor Biopharma Inc., Enlight Biosciences, LLC, Mandara Sciences, LLC and Knode Inc.
- Revenue in GBP (TTM)15.54m
- Net income in GBP-5.64m
- Incorporated2015
- Employees225.00
- LocationPureTech Health PLC501 Boylston St Ste 6102BOSTON 02116-3769United StatesUSA
- Phone+1 (617) 482-2333
- Fax+1 (617) 482-3337
- Websitehttp://puretechhealth.com/
Mergers & acquisitions
| Acquired company | PRTC:LSE since announced | Transaction value |
|---|---|---|
| Ariya Therapeutics Inc | -1.18% | 666.98m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alliance Pharma plc | 129.76m | 21.67m | 368.89m | 210.00 | 17.33 | 1.43 | 15.67 | 2.84 | 0.041 | 0.041 | 0.2453 | 0.4969 | 0.3214 | 2.94 | 6.26 | 617,904.80 | 5.37 | 6.62 | 7.00 | 7.87 | 62.83 | 58.75 | 16.70 | 21.10 | 0.4659 | 8.46 | 0.2672 | 31.80 | 16.30 | 21.16 | -36.33 | 13.88 | -21.58 | 10.02 |
| Indivior PLC | 720.84m | 195.82m | 376.39m | 1.02k | 1.98 | 2.38 | 1.77 | 0.5222 | 0.2603 | 0.2603 | 0.9568 | 0.2165 | 0.5937 | 1.90 | 3.76 | 703,943.60 | 16.13 | 19.01 | 31.44 | 58.16 | 85.67 | 89.95 | 27.17 | 19.15 | 1.86 | -- | 0.590 | 9.09 | -8.05 | -3.74 | 273.97 | -11.00 | 68.71 | -- |
| Oxford BioMedica plc | 63.59m | -7.81m | 406.87m | 377.00 | -- | 5.07 | -- | 6.40 | -0.1146 | -0.1146 | 0.9181 | 1.04 | 0.553 | 6.02 | 3.04 | 168,684.30 | -6.79 | -14.68 | -9.41 | -19.78 | 61.64 | 60.85 | -12.28 | -24.62 | 2.12 | -1.07 | 0.0955 | -- | 77.65 | 65.52 | 183.63 | -- | 61.04 | -- |
| Advanced Medical Solutions Group plc | 103.69m | 20.57m | 516.48m | 654.00 | 25.28 | 2.83 | 20.26 | 4.98 | 0.0951 | 0.0951 | 0.4794 | 0.8511 | 0.5146 | 2.78 | 4.92 | 158,548.90 | 10.21 | 12.43 | 10.96 | 13.63 | 60.40 | 59.28 | 19.84 | 20.59 | 6.08 | 106.25 | 0.0497 | 12.00 | 5.87 | 11.51 | 11.69 | 14.62 | 18.16 | 17.08 |
| Vectura Group PLC | 172.30m | -78.00m | 531.01m | 453.00 | -- | 1.11 | 1,062.02 | 3.08 | -0.1267 | -0.1267 | 0.28 | 0.7798 | 0.2739 | 2.92 | 4.53 | 380,353.20 | -12.40 | -- | -13.67 | -- | 56.99 | -- | -45.27 | -- | 2.41 | -- | 0.017 | -- | 8.45 | -- | -1.03 | -- | -- | -- |
| Puretech Health PLC | 15.54m | -5.64m | 714.26m | 225.00 | -- | 2.62 | -- | 45.96 | -0.0227 | -0.0227 | 0.054 | 0.9557 | 0.0383 | -- | 4.32 | 69,070.27 | -13.04 | -28.57 | -17.99 | -45.76 | -- | -- | -340.74 | -865.69 | -- | -- | 0.2374 | -- | 718.46 | 19.53 | -264.91 | -- | 50.17 | -- |
| Clinigen Group PLC | 456.90m | 5.20m | 1.07bn | 130.00 | 195.32 | 2.43 | 22.75 | 2.34 | 0.0412 | 0.0412 | 3.50 | 3.31 | 0.5272 | 9.69 | 4.43 | 3,514,616.00 | 0.600 | 2.14 | 0.7558 | 2.96 | 39.90 | 36.02 | 1.14 | 3.34 | 0.8049 | 8.29 | 0.4338 | 53.60 | 19.86 | 29.26 | -81.02 | -20.34 | -2.90 | 16.67 |
| Holder | Shares | % Held |
|---|---|---|
| Invesco Asset Management Ltd.as of 10 Apr 2018 | 90.10m | 31.88% |
| Lansdowne Partners (UK) LLPas of 10 Apr 2018 | 27.40m | 9.69% |
| Baillie Gifford & Co.as of 10 Apr 2018 | 19.77m | 7.00% |
| Jupiter Asset Management Ltd.as of 10 Apr 2018 | 15.53m | 5.50% |
| M&G Investment Management Ltd.as of 01 Aug 2019 | 5.65m | 2.00% |
| Hargreave Hale Ltd.as of 01 Aug 2019 | 5.08m | 1.80% |
| Ruffer LLPas of 01 Aug 2019 | 4.00m | 1.42% |
| DNCA Finance SAas of 30 Jun 2019 | 3.50m | 1.24% |
| Bessemer Investment Management LLCas of 30 Apr 2019 | 2.71m | 0.96% |
| Majedie Asset Management Ltd.as of 31 Aug 2019 | 2.36m | 0.84% |
